KARUNA THERAPEUTICS, INC.

View full entity profile (contributions, contracts, SEC) →

Lobbying Spend

—

Filings

Firms Hired

Active Period

2023–2024

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2024	—	2	1
2023	—	3	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
AVENUE SOLUTIONS	—	5

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
SENATE	2
HOUSE OF REPRESENTATIVES	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	4

Bills Explicitly Cited (2)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 2882118th Congress

Further Consolidated Appropriations Act, 2024

2024 · first_quarter · Firm: AVENUE SOLUTIONS

Open original LDA filing ↗

Cited source text and reported amounts

Education around innovation in schizophrenia; Issues related to mental health; Expiring healthcare extenders; H.R. 4366, the Consolidated Appropriations Act, 2024 (P.L. 118-42); H.R. 2882, the Further Consolidated Appropriations Act, 2024 (P.L. 118-47)

Client expense: — · Firm income: $50,000

Matched citations: H.R. 2882

H.R. 4366118th Congress

Consolidated Appropriations Act, 2024

2024 · first_quarter · Firm: AVENUE SOLUTIONS

Open original LDA filing ↗

Cited source text and reported amounts

Education around innovation in schizophrenia; Issues related to mental health; Expiring healthcare extenders; H.R. 4366, the Consolidated Appropriations Act, 2024 (P.L. 118-42); H.R. 2882, the Further Consolidated Appropriations Act, 2024 (P.L. 118-47)

Client expense: — · Firm income: $50,000

Matched citations: H.R. 4366

Source: Senate LDA

KARUNA THERAPEUTICS, INC. — Lobbying Disclosure | Poliscope